文献速递神经肿瘤

真实世界背景下的胶质母细胞瘤:奥地利人群的治疗模式与结局

Glioblastoma in the real-world setting: patterns of care and outcome in the Austrian population.
PubMed 文献 · J Neurooncol · 2024-08-27

这项回顾性、基于人群的全国性研究纳入2014至2018年奥地利ABTR-SANOnet数据库中所有新诊断的成人胶质母细胞瘤患者共1420例,评估治疗模式并随访至2019年底。全队列中位总生存期为11.6个月,IDH野生型患者为10.9个月,≤65岁接受术后标准治疗者达16.1个月,>65岁接受术后治疗者为11.2个月。随访≥5年发现13/264(4.9%)长期生存者。

要点

  • 全队列中位总生存期11.6个月,IDH野生型患者为10.9个月。
  • ≤65岁接受术后标准治疗者中位总生存期16.1个月,>65岁接受术后治疗者为11.2个月。
  • 1041/1420例(73.3%)按标准化方案在术后约一个月(中位31天)启动术后治疗。

核心结论

  • 数据证实近期奥地利胶质母细胞瘤患者在全国范围内接受了有效的标准治疗。
  • 疾病进展时采用的治疗方法高度可变,最常伴随抗血管生成治疗。
  • 长期生存见于少数比例的患者,多为较年轻、通常实现肿瘤全切除、术后ECOG评分良好并接受标准治疗者。

研究设计与样本

  • 回顾性、基于人群的全国性合作研究,纳入2014至2018年新诊断并登记于ABTR-SANOnet数据库的所有奥地利胶质母细胞瘤患者。
  • 组织学分型采用2016年第4版WHO中枢神经系统肿瘤分类标准,所有患者随访至2019年底。

主要发现

  • 共识别1420例成人胶质母细胞瘤病例,其中男性813例(57.3%),女性607例(42.7%)。
  • 诊断时中位年龄64岁(范围18-88岁)。
  • 全队列中位总生存期为11.6个月,经证实为IDH野生型患者的中位总生存期为10.9个月。
  • ≤65岁接受术后标准治疗的患者组中位总生存期为16.1个月,>65岁接受术后治疗的患者组中位总生存期为11.2个月。
  • 随访≥5年发现13/264例(4.9%)长期生存者。

关键数值与推荐

  • 脑肿瘤手术常辅以5-氨基乙酰丙酸(5-ALA)荧光引导,使用率高达55%。
  • 术后治疗在手术后约一个月启动(中位31天),1041/1420例(73.3%)遵循标准化方案。
  • 830例(58.5%)患者按既定标准治疗开始同步放化疗。
  • 疾病进展时,170/1420例(12.0%)接受第二次手术,467例(33.0%)接受全身治疗,173例(12.2%)接受再放疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We present results of a retrospective population-based investigation of patterns of care and outcome of glioblastoma patients in Austria. PATIENTS AND METHODS: In this nation-wide cooperative project, all Austrian glioblastoma patients newly diagnosed between 2014 and 2018 and registered in the ABTR-SANOnet database were included. Histological typing used criteria of the WHO classification of CNS tumors, 4th edition 2016. Patterns of care were assessed, and all patients were followed until the end of 2019. RESULTS: 1,420 adult glioblastoma cases were identified. 813 (57.3%) patients were male and 607 (42.7%) female. Median age at diagnosis was 64 years (range: 18-88). Median overall survival (OS) was 11.6 months in the total cohort and 10.9 months in patients with proven IDH-wildtype. Median OS in the patient group ≤ 65 years receiving postoperative standard of care therapy was 16.1 months. In the patient group > 65 years with postoperative therapy, median OS was 11.2 months. Follow-up ≥ 5 years identified 13/264 (4.9%) long-term survivors. Brain tumor surgery frequently was assisted by 5-aminolevulinic acid (5-ALA) fluorescence (up to 55%). Postoperative treatment was initiated around one month after surgery (median: 31 days) following standardized protocols in 1,041/1,420 (73.3%) cases. In 830 patients (58.5%), concomitant radiochemotherapy was started according to the established standard of care. Treatment in case of progressive disease was considerably variable. 170/1,420 patients (12.0%) underwent a second surgical procedure, 467 (33.0%) received systemic treatment after progression, and 173 (12.2%) were re-irradiated. CONCLUSION: Our data illustrate and confirm nation-wide translation of effective standard of care to Austrian glioblastoma patients in the recent past. In the case of progressive disease, highly variable therapeutic approaches were used, most frequently accompanied by anti-angiogenic therapy. Long-term survival was observed in a minor proportion of mostly younger patients who typically had gross total tumor resection, a favorable postoperative ECOG score, and standard of care therapy.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Hainfellner A, Borkovec M, Seebrecht L, et al. Glioblastoma in the real-world setting: patterns of care and outcome in the Austrian population. J Neurooncol. 2024. PMID: 39192069. doi:10.1007/s11060-024-04808-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。